TKM Ebola

Drug Profile

TKM Ebola

Alternative Names: Ebola SNALP; siEbola-2; siRNA Ebola virus infection therapeutic - Arbutus Biopharma; TKM-100201; TKM-100802; TKM-Ebola; TKM-Ebola Kikwit

Latest Information Update: 29 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ebola virus infections

Highest Development Phases

  • Suspended Ebola virus infections

Most Recent Events

  • 24 Oct 2016 Phase-I development suspended for Ebola virus infections in USA (Arbutus BioPharma pipeline; October 2016)
  • 12 Oct 2016 TKM Ebola is available for licensing as of 12 Oct 2016. http://arbutusbio.com/partners/partnering-licensing-opportunities.php
  • 08 Aug 2016 Arbutus receives patent issuance for Lipid nanoparticle (LNP) delivery technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top